Furthermore, we discovered that S109 exerts its anti-tumor effects by perturbing the three core pathways implicated in glioma: the RTK/AKT/Foxos signaling pathway and the p53 and Rb1 tumor-suppressor pathways. The gene discussed is TP53; the disease is neoplasm.